Stocktoria

Tango Therapeutics, Inc. TNGX

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-03
Chart by TradingView
3/9
Piotroski F — financial health
5.58
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Valuation · market cap as of 2026-06-29

Market cap$5.1B
P / S82.1×
P / B14.8×

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$62.4M$42.1M$36.5M$24.9M$37.0M
Operating income-$111.3M-$145.6M-$114.2M-$111.1M-$58.2M
Net income-$101.6M-$130.3M-$101.7M-$108.2M-$58.2M
Operating cash flow-$138.9M-$131.5M-$118.0M-$109.1M-$59.5M
Free cash flow-$139.9M-$132.3M-$119.5M-$116.8M-$61.4M
Total assets$398.7M$316.5M$402.6M$436.5M$500.2M
Total liabilities$52.5M$117.0M$149.5M$187.0M$155.4M
Shareholders' equity$346.2M$199.5M$253.1M$249.5M$344.7M
Ratios
Operating margin-178.4%-346.1%-312.6%-446.8%-157.1%
Net margin-162.9%-309.7%-278.5%-435.1%-157.2%
FCF margin-224.3%-314.4%-327.2%-469.7%-165.7%
Return on assets-25.5%-41.2%-25.3%-24.8%-11.6%
Return on equity-29.3%-65.3%-40.2%-43.4%-16.9%
Current ratio16.326.987.546.7612.10
Revenue growth48.3%15.2%46.9%-32.9%383.8%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.533,937$11.2M

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 5.58 (safe)

  • Working capital / assets 0.833
  • Retained earnings / assets -1.513
  • EBIT / assets -0.279
  • Equity / liabilities 6.593

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001819133 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.